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Background: Some epidemiological studies have demonstrated the association between 
psoriasis vulgaris and coronary artery disease (CAD). However, there is a lack of specific 
data regarding the association between psoriasis vulgaris and myocardial infarction (MI), the 
more severe and critical presentation of CAD, in the Japanese population. 
Methods and results: We retrospectively analyzed 113,065 patients of all ages at our 
hospital from January 1, 2011 to January 1, 2013. We extracted the data of patients with 
psoriasis vulgaris, diabetes mellitus, dyslipidemia, or MI (acute, sub-acute, or old), including 
sex and age from the electronic medical record database. The prevalence of MI in patients 
with hypertension, dyslipidemia, diabetes mellitus, and psoriasis vulgaris were 4.8% 
(794/16,476), 5.0% (459/9,236), 4.6% (531/11,555), and 2.7% (32/1197), respectively. 
Multivariate analysis showed that psoriasis vulgaris was significantly associated with MI 
(adjusted odds ratio [OR]: 1.87; 95% confidence interval [CI]: 1.26–2.68; p=0.0022). In a 
subgroup analysis of 24,069 patients who had one or more comorbidities including diabetes 
mellitus, dyslipidemia, and hypertension, psoriasis vulgaris was still independently associated 










Psoriasis vulgaris is regarded as an immune-mediated chronic low-level inflammatory skin 
disorder associated with metabolic and cardiovascular comorbidities [1-3]. Some 
epidemiological studies have shown that, although there was a racial difference in the 
prevalence of psoriasis [4-8], there was a clear association between psoriasis vulgaris and 
coronary artery disease (CAD) regardless of race [9-12], as we previously reported in 
hospital-based Japanese population [13]. In addition, the association with the risk of 
myocardial infarction (MI), a more severe and clinically significant condition of CAD, and 
psoriasis was reported in US, Europe, central China, and Taiwan [14-22]. However, there is a 
lack of data regarding the association between MI and psoriasis vulgaris in the Japanese 
population. In the present study, we tested the hypothesis that psoriasis vulgaris is 






Patients and data collection 
From the medical accounting system we retrospectively researched all clinic and in-hospital 
113,065 patients of all ages from January 1, 2011 to January 1, 2013 in this cross-sectional 
observational study. First, we identified the total number of patients from the medical 
accounting system. Second, we extracted the data of patients with psoriasis, metabolic 
comorbidities, or myocardial infarction regarding sex, age, and diagnoses including psoriasis 
vulgaris (International Classification of Diseases [ICD]-10 code L40.0), hypertension (ICD-
10 codes I10, I11, I12, I13, I14, and I15), dyslipidemia (ICD-10 code E78), diabetes mellitus 
(ICD-10 codes E10, E11, E12, E13, and E14), and acute, sub-acute, or old myocardial 
infarction (ICD-10 codes I21, I22, and I25.2, respectively) from the medical record database. 
Hypertension, dyslipdemia, and diabetes mellitus are the typical risk factor for MI and 
regarded as potential confounders. If the diagnoses of each disease were recorded in the 
medical charts, we considered each disease as present. Patients were automatically and 
without intension extracted from the medical accounting system. We evaluated the risk of MI 
in patients with psoriasis vulgaris. The present study was approved by the institutional review 
board of Kitano Hospital (P15-06-005) in concordance with the Declaration of Helsinki. 
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Patient consent was not obtained because of the retrospective study. We disclosed the detail 
of the present study to the public as an opt-out method and the notice clearly informed 




A chi-square test was performed for categorical variables summarized as counts and 
percentages. The Wilcoxon rank sum test was used for continuous variables summarized as 
mean and standard deviation. To analyze the comorbid factors associated with MI, we used a 
multivariable logistic regression model that involved the following variables: psoriasis 
vulgaris, diabetes mellitus, dyslipidemia, and hypertension. In this first analysis, we did not 
include sex and age in the model because of the lack of the data in a total population. Second, 
to analyze the association between psoriasis and MI in patients with one comorbidity or more 
including diabetes mellitus, dyslipidemia, and hypertension, we performed a sub-analysis 
with a multivariable logistic regression model that involved age, sex, psoriasis vulgaris, 
diabetes mellitus, dyslipidemia, and hypertension in adults (the age more than or equal to 20 
years). In the subgroup analysis, we used risk-adjusting variables for excluding each 
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subgrouping factor without adjustment for multiple tests. We also evaluated the interactions 
between the subgroup factors and the effect of psoriasis for the MI. The adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated. A two-tailed p value less than 
0.05 was considered statistically significant in all analyses. Statistical analyses were 





The comorbidities of this study population are shown in Table 1. Patients with psoriasis had a 
higher prevalence of hypertension, hyperlipidemia, diabetes mellitus, and MI. Figure 1 
indicates the comorbidities of patients with psoriasis and as the figure shows, MI was present 
in 966 (0.85%) patients. The prevalence of MI in patients with hypertension, dyslipidemia, 
diabetes mellitus, and psoriasis vulgaris was 4.8% (794/16,476), 5.0% (459/9,236), 4.6% 
(531/11,555), and 2.7% (32/1197), respectively (Table 1).  
 
By multivariate analysis, after adjusting for psoriasis vulgaris, diabetes mellitus, 
dyslipidemia, and hypertension, we established that psoriasis vulgaris was significantly 
associated with MI (adjusted OR: 1.87; 95% CI: 1.26–2.68; p=0.0022), along with 
hypertension (adjusted OR: 14.57; 95% CI: 12.12–17.58; p<0.0001), dyslipidemia (adjusted 
OR: 2.12; 95% CI: 1.84–2.44; p<0.0001), and diabetes mellitus (adjusted OR: 2.46; 95% CI: 
2.13–2.84; p<0.0001) (Figure 2).  
 
In the second analysis of 23,916 adult patients who had one or more comorbidities including 
diabetes mellitus, dyslipidemia, and hypertension, psoriasis vulgaris was still independently 
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associated with MI adjusted OR; 1.49; 95% CI: 1.02–2.18; p=0.0358, Table 2) after adjusting 
for diabetes mellitus, dyslipidemia, hypertension, sex, and age.  
In subgroup analyses, there were no interactions between the subgrouping factors and the 






In the present study, we demonstrated the independent association between MI and psoriasis 
vulgaris in a Japanese patient-population. 
 
Many patients with psoriasis vulgaris have overlapping risk factors for MI. In the present 
study, psoriasis was independently associated with MI in a cohort of 113,065 patients and in a 
sub-population of 24,069 patients with one and more comorbidities in Japan. This result was 
consistent with research performed in Europe, North America, and Asia [14-22]. However, 
there were conflicting results in other published studies that did not show a significant 
relationship between psoriasis and MI [23-27]. In a large population-based Dutch cohort 
study, Wakkee et al. (2010), showed that the risk of MI was not significant in patients with 
psoriasis (HR: 0.94; 95% CI: 0.80–1.11) [25]. The presence or absence of arthritis is one 
reason why the discrepancies existed. [28]. Chin et al. and Ogdie et al. reported that psoriasis 
patients with arthritis had a greater risk of cardiovascular comorbidities or MI than psoriasis 
patients without arthritis [29, 30]. Other reasons for the conflicting results may be due to the 
severity and the duration of psoriasis. A recent study by Eqeberg et al. (2017), which included 
61,603 patients with psoriasis and 4,300,085 controls, revealed a significant association 
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between MI and psoriasis only in patients with severe psoriasis (HR: 1.21, 95% CI: 1.07–
1.37) [24]. Armstrong et al. (2012) indicated that patients who had psoriasis for over an 8-
year period had a greater prevalence of CAD [9]. However, the association between 
myocardial infarction and psoriasis has been almost never studied in Japan. Future studies are 
necessary to research the general Japanese population and consider, age, sex, smoking, and 
psoriasis severity, duration, and treatment in order to show that psoriasis is truly an 
independent risk factor for myocardial infarction in the general Japanese population. In the 
present study, we could not assess the incidence of MI during the follow-up period due to the 
cross-sectional design. In addition, the severity of psoriasis was not mentioned in the data 
collected from the electrical medical record. However, after adjusting for available 
confounders, psoriasis was still independently associated with MI in a large Japanese 
population.  
 
Psoriasis is a systemic inflammatory disease that mainly affects the skin. Inflammatory 
mediators produced by Type 1 helper T (Th1) and Type 17 helper T (Th17) cells cause 
systemic inflammation and vascular atherosclerosis [31-33]. Since the susceptibility to 
psoriasis may differ due to the genetic background [7-8] and the prevalence of psoriasis in 
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Japan is not high [13,34], the attributable risk of PV for MI may be small in Asian countries. 
However, the patients with PV should be carefully managed for controlling the 
atherosclerotic risks, especially myocardial infarction, the life-threatening disease condition, 
during clinical practice. 
 
The present study has several limitations. First, the population in our study was not the 
general Japanese population, but a patient-population in a Japanese hospital. The prevalence 
of each disease in our study may be higher than that of the general Japanese population [34]. 
A nation-wide study would be helpful to generalize the results in this study. Second, we could 
not collect data regarding smoking, blood tests, and body weight; in addition, information on 
age and sex was disease-specifically extracted. This lack of data might have resulted in 
insufficient adjustment. Third, diagnostic codes consistent with the diseases may have 
included only registered codes acceptable to the Japanese health care insurance system. The 
ICD diagnosis codes have not been validated. However, Kubota et al surveyed demographic 
characteristics of PV using ICD-10 codes and they found the demographic findings were 
common to the whole population and dermatology/rheumatology department [34]. They 
suggested that all patients identified by the claims diagnosis codes in their study roughly 
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represented all patients with psoriasis who used healthcare services. However, we did not 
have the data of codes from which department the codes were reported. Fourth, it was 
possible that serious diseases including myocardial infarction might often accompany with 
the intensive systemic physical examination that revealed the existence of PV. Fifth, the 
information regarding the severity and treatment of psoriasis vulgaris was not collected. 
Finally, the time course of each disease was not taken into account because of the cross-
sectional design. Larger, longitudinal cohort studies could address the cause-effect 
relationship between psoriasis and MI.  
 
Conclusion 
Psoriasis vulgaris was independently associated with the presence of MI within a patient-
population in Japan. 
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Figure 1. Extraction of patients by international classification of diseases (ICD) -10 codes. 
MI: Myocardial Infarction, HT: Hypertension, DLp: Dyslipidemia, DM: Diabetes Mellitus, 
PV: Psoriasis Vulgaris 
Figure 2. The independent association between psoriasis and myocardial infarction after 
adjusting for hypertension, dyslipidemia, and diabetes mellitus. OR: odds ratio; CI: 
confidence interval. 






Table 1. Baseline characteristics of patients with psoriasis 
 With psoriasis Without psoriasis 
 Total MI Total MI 









































































Table 2. Adjusted risk of myocardial infarction in adult patients who had one or more 
comorbidities including diabetes mellitus, dyslipidemia, and hypertension  
Factors Adjusted OR (95% CI) P value 
Age (1-y increment) 1.03 (1.02-1.04) <0.0001 
Male 3.21 (2.73-3.77) <0.0001 
Hypertension 4.94 (3.89-6.27) <0.0001 
Dyslipidemia 1.98 (1.72-2.28) <0.0001 
Diabetes Mellitus 1.79 (1.55-2.07) <0.0001 
Psoriasis 1.49 (1.02-2.18) 0.0358 
OR: odds ratio; CI: confidence interval 
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